enGene Holdings Inc.

enGene Holdings Inc. held its 2026 Annual General Meeting on June 9, 2026. A total of 56,196,302 common shares, representing approximately 83.89% of outstanding shares, were present or represented by proxy. Shareholders voted to elect all four director nominees and approved the appointment and remuneration of the auditor.

enGene Therapeutics Inc. announced its Annual General Meeting of Shareholders will be held virtually on June 9, 2026, at 8:30 a.m. Eastern time. Shareholders will vote on receiving the audited financial statements for the year ended October 31, 2025, electing four director nominees, and appointing KPMG LLP as the company's auditor. The record date for shareholders entitled to vote is April 28, 2026, and voting instructions are provided for both registered and beneficial owners.

enGene Therapeutics announced updated interim results from the pivotal cohort of its Phase 2 LEGEND trial for detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients. The trial showed a 54% complete response (CR) rate at any time and a 43% CR rate at six months, with a low progression rate to muscle-invasive disease (3.2%). However, the Kaplan-Meier estimate for the 12-month CR rate was 25%, which the CEO noted was "not what we hoped." The company also amended the employment agreement for Dr. Hussein Sweiti, increasing his base salary to $561,750 and annual bonus opportunity to 40%.